Oncology Data Advisor™ · Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with ...
The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®, ImmunoGen), a folate receptor alpha (FRα)–directed antibody and microtubule inhibitor conjugate, for patients with FRα-positive, platinum-resistant epithelial ovari...
Cancer of the uterine corpus, also called endometrial cancer, is the most common cancer of the female genital tract, with the American Cancer Society estimating that there will be 65,950 new diagnoses and 12,550 fatal cases in the United States in 20...
The FDA has granted approval to pembrolizumab (Keytruda®, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express programmed death-ligand 1 (PD-...

Copyright © 2022 Oncology Data Advisor. All rights reserved.